Tag Archives: Biogen stock

What Happened To Bioverativ Stock? A Short-Lived Spinoff Yielded Big Profit For Shareholders

From its spinoff from Biogen(BIIB) in February 2017 to the closing of its acquisition by Sanofi(SNY) in March 2018, Bioverativ’s tenure as a public company was short but profitable. From an initial price of $44.98 to the sale price of $105 in cash, Bioverativ stock, trading under the symbol BIVV, increased 133%. Not bad for 13 months.  We… Read More »

Struggling Perrigo Plans To Spin Off Or Sell Prescription Pharmaceuticals Business

Perrigo Company(PRGO) is another company with a spinoff heritage returning to our pages. Back in 2013, Perrigo acquired the Elan Corporation for $8.6 billion. Elan had completed its spinoff of Prothena(PRTA) in late 2012.  Perrigo subsequently sold the Tysabri royalty stream acquired with Elan to Royalty Pharma for up to $2.85 billion. Today, Perrigo’s market capitalization stands at… Read More »

Bioverativ(BIVV) To Be Acquired By Sanofi(SNY) At Huge 64% Premium

It was just one year ago when Biogen(BIIB) spun off hemophilia and blood disorder specialist Bioverativ(BIVV). With the stock trading in the 40s post-spin, we highlighted some disparate analyst opinions of the spin. The most bullish, Gabelli & Company, has a price target of $58 for Bioverativ stock.  This past Friday, Bioverativ stock closed at $64.11, above Gabelli’s… Read More »

Bioverativ(BIVV) Adds a Fifth Director, Reports Additional Positive Long Term Data On ALPROLIX

Following its spin off from Biogen(BIIB) in January, Bioverativ(BIVV) had merely four Directors- CEO John Cox and three independent Directors. This represented an unusually small Board for a company with a market cap of over $5 billion, and it was probably inevitable that the Board would grow. Last week, Bioverativ added a fifth director,  Anna Protopapas. Ms. Protopapas… Read More »

Bioverativ(BIVV) Proves Attractive To Former Valeant(VRX) Patron ValueAct Capital

Even before Biogen(BIIB) completed its spinoff of Bioverativ(BIVV), ValueAct Capital began buying “when-issued” stock in the new company. The hedge fund has continued to buy both stock and forward contracts and has now accumulated a 7.1% position in Bioverativ. The shares were purchased at between $40 and $45 per share. As Bioverativ stock has now risen above $50,… Read More »

Which Way Is Biogen(BIIB) Headed After Spinoff Of Bioverativ(BIVV)?

Last week, Biogen(BIIB) completed its spinoff of Bioverativ(BIVV). The Bioverativ spinoff included Biogen’s hemophilia assets and a $325 million pile of cash. What remains at Biogen is, depending on who you listen to, either poised for great growth, or struggling with it. Barrons reports on two analysts with positive views on Biogen: RBC Capital Markets analyst Michael Yee… Read More »

Gabelli & Co Call Bioverativ(BIVV) Stock A Buy With A Value Of $58, Morgan Stanley Disagrees

Bioverativ(BIVV), a drug company focused on hemophilia and other blood disorders, was spun off by Biogen(BIIB) last week. Gabelli & Co initiated Bivoerativ stock as a buy with a value of $58, citing the company’s strong balance sheet(no debt, $325 million in cash), its limited exposure to Medicare, its potential to benefit from corporate tax reform, and its… Read More »